NBIX
Neurocrine Biosciences IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$12.89B
P/E Ratio
27.38
EPS
$4.68
Beta
0.35
52W High
$160.18
52W Low
$105.45
50-Day MA
$130.08
200-Day MA
$137.35
Dividend Yield
—
Profit Margin
16.70%
Forward P/E
20.75
PEG Ratio
0.41
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $2.86B |
| Gross Profit (TTM) | $1.79B |
| EBITDA | $666.60M |
| Operating Margin | 28.20% |
| Return on Equity | 16.40% |
| Return on Assets | 9.53% |
| Revenue/Share (TTM) | $28.75 |
| Book Value | $32.50 |
| Price-to-Book | 3.96 |
| Price-to-Sales (TTM) | 4.50 |
| EV/Revenue | 4.13 |
| EV/EBITDA | 17.72 |
| Quarterly Earnings Growth (YoY) | 47.70% |
| Quarterly Revenue Growth (YoY) | 28.30% |
| Shares Outstanding | $100.58M |
| Float | $99.08M |
| % Insiders | 1.10% |
| % Institutions | 101.18% |
Historical Volatility
HV 10-Day
30.18%
HV 20-Day
28.32%
HV 30-Day
27.48%
HV 60-Day
33.11%
HV Rank
34.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($185.65 target)
4
Strong Buy20
Buy4
HoldData last updated: 4/29/2026